Confidex: Uses, Dosage & Side Effects
A 4-factor prothrombin complex concentrate (PCC) containing human coagulation factors II, VII, IX, and X for urgent reversal of vitamin K antagonist therapy and treatment of acquired coagulation factor deficiency
Confidex is a 4-factor prothrombin complex concentrate (PCC) derived from human plasma. It contains the vitamin K-dependent coagulation factors II (prothrombin), VII, IX, and X, along with the natural anticoagulant proteins C and S. Confidex is used primarily for the urgent reversal of anticoagulation caused by vitamin K antagonists (such as warfarin, acenocoumarol, or phenprocoumon) in patients experiencing life-threatening bleeding or requiring emergency surgery. It is also indicated for treatment and perioperative prophylaxis of bleeding when there is an acquired deficiency of prothrombin complex factors. Confidex is administered as an intravenous injection in a hospital setting and requires a prescription.
Quick Facts: Confidex
Key Takeaways
- Confidex is a 4-factor prothrombin complex concentrate (PCC) that rapidly reverses anticoagulation from vitamin K antagonists (warfarin) in life-threatening bleeding or before emergency surgery, with onset of action within minutes of intravenous administration.
- It contains human coagulation factors II, VII, IX, and X along with protein C and protein S, providing a balanced coagulation factor replacement that helps prevent both bleeding and excessive clotting.
- Dosing is individualized based on the patient's current INR, target INR, and body weight, with the maximum single dose not exceeding 3,000 IU (approximately 120 mL); INR should be rechecked within 30 minutes after infusion.
- The main risks include thromboembolic events (DVT, PE, MI, stroke), especially in patients with pre-existing risk factors; disseminated intravascular coagulation (DIC) must be excluded before administration.
- As a plasma-derived product manufactured from human blood donations, Confidex undergoes rigorous viral inactivation and screening steps, but a theoretical risk of transmitting infectious agents cannot be entirely eliminated.
What Is Confidex and What Is It Used For?
Confidex belongs to the pharmacological group of blood coagulation factors, specifically the class known as prothrombin complex concentrates (PCCs). It is a lyophilized (freeze-dried) concentrate prepared from pooled human plasma through a sophisticated manufacturing process that includes multiple viral inactivation and removal steps. The product is classified as a 4-factor PCC because it contains all four vitamin K-dependent procoagulant factors: factor II (prothrombin), factor VII, factor IX, and factor X. In addition, Confidex contains the vitamin K-dependent anticoagulant proteins C and S, which play a critical role in the natural regulation of coagulation and help prevent excessive clot formation.
The coagulation cascade is a complex series of enzymatic reactions that ultimately leads to the formation of a fibrin clot to stop bleeding. Vitamin K-dependent coagulation factors are essential components of this cascade. Factor VII initiates the extrinsic coagulation pathway by forming a complex with tissue factor exposed at sites of vascular injury. Factor IX is a key component of the intrinsic pathway, activating factor X in the presence of factor VIIIa, calcium, and phospholipids. Factor X occupies a central position where the intrinsic and extrinsic pathways converge, converting prothrombin (factor II) to thrombin. Thrombin is the final serine protease that converts fibrinogen to fibrin, forming the structural framework of a blood clot. Without adequate levels of these factors, the body cannot form clots effectively, leading to potentially life-threatening bleeding.
Vitamin K antagonists (VKAs) such as warfarin, acenocoumarol, and phenprocoumon are widely prescribed oral anticoagulants that work by inhibiting the enzyme vitamin K epoxide reductase (VKORC1), which is necessary for the recycling of vitamin K. Since vitamin K is required for the hepatic synthesis of functional coagulation factors II, VII, IX, and X, VKA therapy leads to the production of undercarboxylated (non-functional) forms of these factors, thereby reducing the blood's ability to clot. While this anticoagulant effect is therapeutically beneficial for preventing thromboembolic events in conditions such as atrial fibrillation, venous thromboembolism, and mechanical heart valves, it also increases the risk of serious bleeding.
When patients on VKA therapy experience major or life-threatening bleeding, or when they require emergency surgical or invasive procedures, rapid reversal of anticoagulation is essential. Vitamin K (phytomenadione) can reverse VKA effects, but it requires 6–24 hours to restore functional coagulation factor synthesis by the liver. Fresh frozen plasma (FFP) provides coagulation factors but requires large volumes (typically 800–1,600 mL), blood group matching, thawing time, and carries a higher risk of transfusion-related complications including transfusion-related acute lung injury (TRALI) and volume overload. Confidex addresses these limitations by providing a concentrated source of the deficient coagulation factors in a small volume (typically 20–40 mL), with rapid onset of action and no need for blood group matching or thawing.
Confidex is approved by the European Medicines Agency (EMA) and regulatory authorities in numerous countries for the following indications:
- Treatment of bleeding and perioperative prophylaxis of bleeding in acquired deficiency of the prothrombin complex coagulation factors: This includes bleeding caused by VKA therapy as well as deficiency states arising from liver disease, vitamin K deficiency, or consumptive coagulopathy, where rapid correction of coagulation factor levels is needed.
- Urgent reversal of vitamin K antagonist anticoagulation: Specifically in cases of major or life-threatening bleeding, or when emergency surgery or invasive procedures are required in patients currently anticoagulated with warfarin or other VKAs. In this setting, Confidex is typically administered alongside intravenous vitamin K to provide both immediate (Confidex) and sustained (vitamin K) correction of coagulation.
Confidex is a 4-factor PCC, meaning it contains clinically significant amounts of all four vitamin K-dependent clotting factors (II, VII, IX, X). Some older PCC products are 3-factor formulations that contain very low levels of factor VII. The 4-factor formulation is preferred for VKA reversal because factor VII has the shortest half-life of the vitamin K-dependent factors and is often the most depleted during VKA therapy. International guidelines, including those from the International Society on Thrombosis and Haemostasis (ISTH), recommend 4-factor PCC as the treatment of choice for urgent VKA reversal.
What Should You Know Before Receiving Confidex?
Contraindications
There are specific situations in which Confidex must not be used. Understanding these contraindications is critical for patient safety, as administration in these circumstances could lead to serious or fatal complications.
- Hypersensitivity: Do not receive Confidex if you have a known allergy to the active substances (human coagulation factors II, VII, IX, X, protein C, protein S) or to any of the excipients, including heparin or heparin-related compounds.
- Heparin-induced thrombocytopenia (HIT): Confidex contains trace amounts of heparin from the manufacturing process. It must not be given to patients with a confirmed history of heparin-induced thrombocytopenia type II (HIT-II), a serious immune-mediated reaction to heparin that causes paradoxical thrombosis.
Warnings and Precautions
There is a risk of thromboembolic events with Confidex, including deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, and disseminated intravascular coagulation (DIC). This risk is elevated in patients with pre-existing thromboembolic risk factors, a history of coronary heart disease, liver disease, perioperative or postoperative patients, neonates, or patients receiving high or repeated doses. The potential benefit of treatment must be carefully weighed against the thromboembolic risk in each individual patient.
Before and during treatment with Confidex, the following warnings and precautions should be considered:
- Disseminated intravascular coagulation (DIC): DIC is a condition in which the coagulation system is abnormally activated throughout the body, leading to both widespread clotting and bleeding. DIC must be excluded before Confidex is administered, because giving coagulation factors to a patient with active DIC could worsen the condition. If signs or symptoms of DIC develop during treatment, infusion should be stopped immediately.
- Thromboembolic events: Patients with a history of ischemic heart disease, cerebrovascular disease, deep vein thrombosis, pulmonary embolism, or other thromboembolic disorders are at increased risk. Patients with liver disease may also be at higher risk because their natural anticoagulant levels (antithrombin III) may be reduced. Close monitoring is essential.
- Allergic reactions: Hypersensitivity or allergic reactions, including anaphylaxis, may occur. If signs of allergy develop (e.g., hives, chest tightness, wheezing, low blood pressure, generalized urticaria), the infusion should be discontinued immediately and appropriate treatment initiated.
- Transmissible agents: Because Confidex is manufactured from human plasma, it carries a theoretical risk of transmitting infectious agents, including viruses and, theoretically, the agent responsible for variant Creutzfeldt-Jakob disease (vCJD). Multiple safety measures are employed, including donor screening, testing of plasma pools, and viral inactivation/removal steps during manufacturing. However, the risk cannot be entirely eliminated.
- Infusion rate: The maximum infusion rate for Confidex is 8 mL per minute (approximately 210 IU/min at the standard reconstituted concentration). Rapid infusion can increase the risk of thromboembolic complications and adverse reactions.
- Monitoring: INR should be monitored before and after administration to assess the adequacy of coagulation correction. Regular monitoring for signs and symptoms of thromboembolic events is recommended, particularly in the 24–48 hours following administration.
- Sodium content: Confidex contains sodium. This should be taken into consideration for patients on a sodium-restricted diet.
Pregnancy and Breastfeeding
The safety of Confidex during pregnancy and breastfeeding has not been established in controlled clinical trials. Animal reproduction studies have not been conducted with Confidex. It is important to note that the underlying indication for Confidex use (life-threatening bleeding or need for emergency surgery) typically represents situations where the potential benefit to the mother outweighs any theoretical risk to the fetus or infant.
During pregnancy, the need for coagulation factor replacement should be assessed on an individual basis, taking into account the clinical situation and the known physiological changes in coagulation that occur during pregnancy. Decisions about use during lactation should also consider the urgency of the clinical indication and the potential exposure of the infant through breast milk, although significant transfer of large protein molecules like coagulation factors into breast milk is considered unlikely.
Women who are pregnant, think they may be pregnant, or are breastfeeding should inform their doctor. In emergency situations where Confidex is required, the treating physician will assess the risk-benefit ratio on an individual basis.
How Does Confidex Interact with Other Drugs?
Drug interactions with Confidex primarily involve its relationship with anticoagulant and hemostatic medications. Because Confidex replaces coagulation factors that are suppressed by vitamin K antagonists, its administration directly counteracts VKA therapy. Additionally, interactions may occur with other agents that affect the coagulation cascade. It is essential that the treating physician is aware of all medications the patient is receiving.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Vitamin K antagonists (warfarin, acenocoumarol) | Confidex directly reverses VKA effect by replacing depleted factors | Intended therapeutic effect; administer vitamin K concurrently for sustained reversal |
| Antifibrinolytic agents (tranexamic acid, aminocaproic acid) | Combined procoagulant effect may increase thrombotic risk | Use combination with caution; monitor closely for thromboembolic events |
| Heparin (unfractionated, LMWH) | Confidex contains trace heparin; concurrent heparin may potentiate anticoagulant effect | Contraindicated in HIT; monitor aPTT if concurrent heparin is used |
| Recombinant factor VIIa (NovoSeven) | Additive procoagulant effect; significantly increased thrombotic risk | Avoid concurrent use unless clearly indicated; monitor for thrombosis |
Minor Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Vitamin K (phytomenadione) | Synergistic reversal of VKA; vitamin K provides sustained effect | Recommended concurrent use for complete VKA reversal |
| Direct oral anticoagulants (rivaroxaban, apixaban) | Partial reversal of factor Xa inhibitor effect (off-label use) | Not a primary indication; specific reversal agents preferred when available |
| Antiplatelet agents (aspirin, clopidogrel) | No direct pharmacological interaction; both affect hemostasis via different pathways | Antiplatelet agents do not negate PCC effect; combined use acceptable when clinically indicated |
No formal drug interaction studies have been conducted with Confidex. The interactions described above are based on pharmacological principles and clinical experience. Patients should be monitored for coagulation parameters (INR, aPTT) and signs of thromboembolic or bleeding events whenever Confidex is used in combination with other hemostatic or anticoagulant agents.
What Is the Correct Dosage of Confidex?
The dose and duration of treatment with Confidex depend on the severity of the coagulation disorder, the clinical situation, and the patient's individual response. Dosing is expressed in International Units (IU) based on the factor IX content of the product. The treating physician determines the appropriate dose based on laboratory parameters (primarily the INR) and the clinical context. Treatment should always be initiated and monitored under the supervision of a physician experienced in the management of coagulation disorders.
Adults
For reversal of vitamin K antagonist anticoagulation in adults, the following dosing table provides general guidance. Doses are approximate and should be adjusted based on individual patient assessment and serial INR monitoring:
| Initial INR | Approximate Dose | Maximum Volume | Target INR |
|---|---|---|---|
| 2.0 – 3.9 | 25 IU/kg body weight | Based on body weight (max 3,000 IU) | ≤ 1.3 |
| 4.0 – 6.0 | 35 IU/kg body weight | Based on body weight (max 3,000 IU) | ≤ 1.3 |
| > 6.0 | 50 IU/kg body weight | Based on body weight (max 3,000 IU) | ≤ 1.3 |
These doses are intended to provide a general guide. The actual dose administered should always be guided by the patient's clinical situation and serial laboratory monitoring. The INR should be checked within approximately 30 minutes of completing the infusion to verify adequate correction. If the INR remains elevated, additional doses may be considered.
Vitamin K should be administered concurrently with Confidex when treating VKA-related bleeding, as Confidex provides only temporary factor replacement. The half-lives of the infused factors range from approximately 4–6 hours (factor VII) to 48–60 hours (factor II). Without concurrent vitamin K administration, the coagulation factors will be consumed and INR will rise again once the infused factors are cleared.
Children
The safety and efficacy of Confidex in children and adolescents have not been established in controlled clinical trials. There are limited data available on the use of prothrombin complex concentrates in the pediatric population. When used in pediatric patients, dosing is generally weight-based using the same principles as for adults, under the guidance of a pediatric hematologist. The thromboembolic risk may differ in neonates and infants due to differences in their coagulation system maturity. Neonates are considered to be at potentially higher risk and require particularly careful monitoring.
Elderly
Elderly patients may be at increased risk of thromboembolic events due to age-related cardiovascular comorbidities, reduced mobility, and other risk factors. No specific dose adjustment is recommended based on age alone, but careful individualized assessment of the risk-benefit ratio is essential. INR monitoring is particularly important in elderly patients to avoid both under-treatment (persistent bleeding) and over-correction (thromboembolic risk). The infusion rate should be carefully controlled and may be reduced if clinically appropriate.
Missed Dose
Confidex is administered in a hospital or clinical setting as a single dose or short treatment course in response to an acute clinical need (e.g., active bleeding, emergency surgery). It is not a medication taken on a regular schedule at home. Therefore, the concept of a “missed dose” does not typically apply. If additional doses are needed, the treating physician will determine the timing and amount based on ongoing INR monitoring and clinical assessment.
Overdose
Overdose with prothrombin complex concentrates can lead to an excessive procoagulant state, significantly increasing the risk of thromboembolic complications including deep vein thrombosis, pulmonary embolism, myocardial infarction, and disseminated intravascular coagulation (DIC). Symptoms of overdose may include chest pain, shortness of breath, leg swelling, sudden severe headache, or visual disturbances.
There is no specific antidote for Confidex overdose. If overdose is suspected, the patient should be closely monitored for signs and symptoms of thromboembolic events and DIC. Supportive measures may include anticoagulation therapy (heparin) if thrombosis occurs, provided the bleeding indication has been adequately managed. Coagulation parameters (INR, aPTT, fibrinogen, D-dimer, platelet count) should be monitored frequently. Treatment of DIC follows established guidelines including potential use of antithrombin concentrate and supportive care.
What Are the Side Effects of Confidex?
Like all medicines, Confidex can cause side effects, although not everybody gets them. The overall safety profile of Confidex reflects both the pharmacological properties of coagulation factor replacement and the characteristics of plasma-derived products. The most clinically significant adverse effects are thromboembolic events, which represent an inherent risk of any treatment that rapidly restores coagulation capacity, and hypersensitivity reactions.
The following side effects have been reported during clinical studies and post-marketing surveillance:
Common
May affect up to 1 in 10 people
- Headache
- Nausea
- Thromboembolic events (including deep vein thrombosis, pulmonary embolism)
- Injection site reactions (pain, redness, swelling)
- Transient increase in liver transaminases
Uncommon
May affect up to 1 in 100 people
- Allergic or hypersensitivity reactions (rash, urticaria, pruritus)
- Fever (pyrexia)
- Myocardial infarction
- Cerebrovascular accident (stroke)
- Disseminated intravascular coagulation (DIC)
- Hypotension
- Tachycardia
Rare
May affect up to 1 in 1,000 people
- Anaphylactic/anaphylactoid reactions (severe allergic reaction with potential circulatory collapse)
- Heparin-induced thrombocytopenia (HIT) due to trace heparin content
- Development of inhibitory antibodies against coagulation factors
- Renal impairment or renal failure
- Tremor, paresthesia
Frequency Not Known
Cannot be estimated from available data
- Transmission of infectious agents (theoretical risk with all plasma-derived products)
- Development of antibodies to plasma proteins
- Nephrotic syndrome (in the context of immune tolerance therapy for hemophilia patients with factor IX inhibitors)
The risk of thromboembolic complications is the most clinically important adverse effect profile consideration. Several factors increase this risk, including high or repeated doses, a personal history of thromboembolic disease, coronary heart disease, liver disease with impaired synthesis of natural anticoagulants, recent surgery (particularly orthopedic procedures), advanced age, prolonged immobilization, and concurrent use of other procoagulant agents. The presence of protein C and protein S in the Confidex formulation is intended to partially mitigate this risk by providing natural anticoagulant regulation.
Regarding the risk of infectious agent transmission, Confidex is manufactured using stringent safety measures. These include screening of individual donations and plasma pools for specific markers of infection (HBsAg, anti-HCV, anti-HIV-1/2, HAV, HBV, HCV, HIV-1, and parvovirus B19 by NAT), as well as dedicated viral inactivation steps during manufacturing (pasteurization and nanofiltration). Despite these measures, the possibility of transmitting infectious agents cannot be entirely ruled out, including currently unknown or emerging pathogens.
Contact your healthcare provider immediately if you experience any of the following after receiving Confidex: sudden chest pain or shortness of breath (possible pulmonary embolism), pain or swelling in a leg (possible deep vein thrombosis), sudden severe headache or visual disturbances (possible stroke), signs of severe allergic reaction (difficulty breathing, swelling of the face or throat, widespread rash with low blood pressure), or any unexplained worsening of symptoms.
How Should You Store Confidex?
Proper storage of Confidex is essential to maintain the stability and efficacy of the coagulation factors. The product is a lyophilized (freeze-dried) powder that is reconstituted with the provided solvent immediately before use.
- Temperature: Store below 25°C (77°F). Do not freeze. Freezing can damage the protein structure of the coagulation factors and render the product ineffective or potentially harmful.
- Light protection: Keep the product in the original outer carton to protect from light. Exposure to light can degrade the coagulation factor proteins.
- Reconstituted solution: After reconstitution with the provided solvent, the solution should be used immediately. Chemical and physical in-use stability has been demonstrated for up to 3 hours at room temperature (not exceeding 25°C). From a microbiological standpoint, the product should be used immediately after reconstitution. If not used immediately, storage times and conditions are the responsibility of the user.
- Appearance: The reconstituted solution should be clear to slightly opalescent. Do not use solutions that are cloudy, contain particles, or have changed color.
- Shelf life: The shelf life of the unopened product is stated on the packaging. Do not use Confidex after the expiry date printed on the vial and outer carton.
- Disposal: Any unused product or waste material should be disposed of in accordance with local regulations for biological waste and pharmaceutical products. Do not dispose of medicines via household waste or wastewater.
Confidex is typically stored and administered in hospital pharmacy settings where appropriate temperature monitoring and controlled storage conditions are maintained. Patients do not usually store this product at home.
What Does Confidex Contain?
Confidex is a complex biological product containing multiple active substances derived from human plasma. Understanding its composition is important for healthcare professionals administering the product and for identifying patients who may be at risk of allergic reactions to specific components.
Active Substances
The active substances in Confidex 250 IU powder and solvent for solution for injection are human coagulation factors derived from pooled human plasma:
| Component | Amount per Vial | After Reconstitution (per mL) |
|---|---|---|
| Factor II (Prothrombin) | 140–360 IU | 7–18 IU/mL |
| Factor VII | 70–200 IU | 3.5–10 IU/mL |
| Factor IX | 250 IU (labeling basis) | 12.5 IU/mL |
| Factor X | 180–480 IU | 9–24 IU/mL |
| Protein C | 150–450 IU | 7.5–22.5 IU/mL |
| Protein S | 120–380 IU | 6–19 IU/mL |
Excipients (Inactive Ingredients)
The powder also contains the following excipients:
- Heparin (trace amounts, approximately 0.5 IU/IU factor IX) – serves as a stabilizer during manufacturing. This is clinically relevant for patients with heparin-induced thrombocytopenia (HIT).
- Antithrombin III (trace amounts) – present as a component of the plasma-derived manufacturing process.
- Sodium citrate – buffer to maintain pH stability.
- Sodium chloride – for isotonicity.
- Sucrose – lyoprotectant that protects the protein structure during freeze-drying.
The solvent provided is sterile water for injection. Confidex is supplied with a reconstitution device (Mix2Vial or similar) that allows aseptic transfer of the solvent to the powder vial. The reconstituted solution has an approximate volume of 20 mL per 250 IU vial.
Frequently Asked Questions About Confidex
Confidex offers several advantages over FFP for vitamin K antagonist reversal. It requires a much smaller volume (typically 20–40 mL vs. 800–1,600 mL for FFP), which reduces the risk of volume overload, particularly in patients with heart failure or renal impairment. Confidex does not require blood group matching or thawing, so it can be administered more quickly. It provides more predictable and consistent correction of INR. Additionally, Confidex has a lower risk of transfusion-related acute lung injury (TRALI), a serious complication associated with FFP. International guidelines, including those from the ISTH and BCSH, now recommend 4-factor PCC as the preferred agent for urgent VKA reversal over FFP.
Confidex works very rapidly because the coagulation factors are administered directly into the bloodstream. The onset of action is essentially immediate, with measurable improvement in coagulation parameters within minutes of completing the infusion. INR correction to the target range (typically ≤1.3) is usually achieved within 10–30 minutes after the infusion ends. This rapid onset is a major advantage in emergency situations such as life-threatening intracranial hemorrhage or acute surgical emergencies where time is critical. However, it is important to administer intravenous vitamin K concurrently, as the effect of Confidex is temporary (the infused factors have limited half-lives ranging from 4–6 hours for factor VII to 48–60 hours for factor II).
Confidex is not specifically indicated or approved for the reversal of direct oral anticoagulants (DOACs) such as rivaroxaban, apixaban, edoxaban, or dabigatran. For dabigatran, the specific reversal agent idarucizumab (Praxbind) is available. For factor Xa inhibitors (rivaroxaban, apixaban, edoxaban), andexanet alfa (Ondexxya/Andexxa) is the approved specific reversal agent. However, in clinical practice, where specific reversal agents may not be immediately available, some guidelines suggest that 4-factor PCC may be considered as an alternative for factor Xa inhibitor-associated life-threatening bleeding. This is an off-label use, and the evidence supporting it is limited. The decision should be made by the treating physician based on the specific clinical circumstances.
Confidex is manufactured from pooled human plasma, so there is a theoretical risk of transmitting blood-borne infectious agents. However, extensive safety measures are employed to minimize this risk. These include rigorous screening of plasma donors, testing of individual donations and plasma pools using nucleic acid testing (NAT) for HIV, hepatitis B, hepatitis C, hepatitis A, and parvovirus B19, and validated viral inactivation and removal steps during manufacturing (pasteurization at 60°C for 10 hours and nanofiltration through 20 nm filters). These measures have been shown to be effective against both enveloped and non-enveloped viruses. While no method can guarantee 100% safety, the risk of viral transmission from modern plasma-derived products like Confidex is considered extremely low.
Vitamin K (phytomenadione) is given concurrently with Confidex for VKA reversal because the two treatments complement each other. Confidex provides an immediate but temporary supply of functional coagulation factors. The infused factors have limited half-lives (factor VII: 4–6 hours; factor IX: 18–24 hours; factor X: 30–50 hours; factor II: 48–60 hours), so without additional intervention, the factors will be consumed and the INR will rise again. Vitamin K restores the liver's ability to produce its own functional coagulation factors, but this takes 6–24 hours to take full effect. Together, Confidex bridges the gap until vitamin K can sustain coagulation factor production, providing both immediate and lasting reversal of VKA anticoagulation.
No, Confidex is intended for administration in a hospital or clinical setting under the supervision of a physician experienced in coagulation disorders. The product requires intravenous administration, careful dose calculation based on INR and body weight, and close monitoring for both adequate coagulation correction and potential thromboembolic complications. The clinical situations that require Confidex (life-threatening bleeding, emergency surgery in anticoagulated patients) are inherently medical emergencies that require hospital-level care. Unlike some other coagulation factor concentrates used for chronic conditions (e.g., factor VIII for hemophilia A), Confidex is not suitable for home use.
References
- European Medicines Agency (EMA). Confidex – Summary of Product Characteristics. Last updated 2025. Available from: www.ema.europa.eu
- Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128(11):1234-1243.
- Goldstein JN, Refaai MA, Milling TJ Jr, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015;385(9982):2077-2087.
- Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. J Am Coll Cardiol. 2020;76(5):594-622.
- Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin – fourth edition. Br J Haematol. 2011;154(3):311-324. Updated 2023 by BCSH.
- Kozek-Langenecker SA, Ahmed AB, Afshari A, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology and Intensive Care. Eur J Anaesthesiol. 2023;40(4):226-304.
- Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. Chest. 2012;141(2 Suppl):e152S-e184S.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Available from: www.who.int
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Hematology and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent panel following ISTH, BCSH, and ESA guidelines
Evidence Framework
GRADE (Grading of Recommendations Assessment, Development and Evaluation) – Level 1A evidence
Accessibility
WCAG 2.2 Level AAA compliance – Screen reader optimized, keyboard navigable
All medical content on iMedic is independently produced without commercial funding. Our editorial team follows strict evidence-based guidelines and undergoes regular peer review. For more information about our editorial standards, visit our Medical Team page.